Bispecific T Cell Engager
Bispecific T Cell Engager - Related Videos
03:01
Evaluation of Immunomodulatory Activity of a Virally Encoded Bispecific T-Cell Engager
0 Views •
2026
Source: Heidbuechel, J. P., et al. Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo. J. Vis. Exp. (2019).This video demonstrates a cell-based assay to evaluate the target-specific immunomodulatory activity of a virally encoded bispecific T-cell engager (BTE). The BTE links tumor cells expressing a target receptor with T cells, triggering tumor lysis and enzyme release. A colorimetric readout, based on substrate conversion, indicates T-cell activation. Higher...
02:44
An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors
0 Views •
2025
This video demonstrates a method for tracking bispecific antibody-induced T cell trafficking to tumors in a mouse model. Luciferase-transduced effector T cells are injected into a mouse with a subcutaneous tumor cell xenograft. Bispecific antibodies are then introduced, binding to T cells and the tumor cells. The localization of the T cells is tracked using bioluminescent imaging, with the magnitude of the signal indicating the extent of T cell infiltration into the tumor.
10:32
Orthogonal Protein Purification Facilitated by a Small Bispecific Affinity Tag
0 Views •
Cited by 7 •
2012
A novel and highly efficient two-step affinity chromatography protocol has been developed and is described in detail. The method is based on a small purification tag with two inherent affinities and is applicable to a wide range of target proteins with different properties.
14:02
Measuring Engagement of Spectators of Social Digital Games
0 Views •
2021
We propose a methodology that enables measuring engagement of spectators in a social digital game combining physiological and self-reported data. As this digital game involves a group of freely moving people, the experience is filmed using a synchronizing technique that links physiological data with events in the game.
10:19
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
0 Views •
2023
Here, we describe a method for transducing human T cells with luciferase to facilitate in vivo tracking of bispecific antibody-induced T cell trafficking to tumors in studies to evaluate the anti-tumor efficacy and mechanism of T cell-engaging bispecific antibodies.
FAQs
The two binding domains create a functional bridge between a tumor-associated antigen and CD3 on a T-cell receptor complex. This induced proximity helps organize an immune synapse, a focused contact zone where the T cell can become activated and release cytotoxic molecules. The design therefore links target recognition with immune effector activity in the same cellular interaction.
Bispecific T-cell engagers redirect T-cell activity through direct binding to CD3 and a tumor-associated antigen rather than relying on peptide presentation by major histocompatibility complex. This distinction matters because the engineered interaction supplies the recognition bridge externally. In cancer research, investigators can therefore study immune-mediated tumor-cell killing through a mechanism that differs from antigen recognition dependent on peptide-MHC presentation.
Antigen selection, the ability to activate T cells, and the quality of the interaction between the two binding targets are central variables. A suitable tumor-associated antigen helps determine which cancer cells can be engaged, while CD3 binding supports recruitment of T-cell activity. Cancer research also examines treatment resistance because tumor or immune features may limit sustained effectiveness.
Studies use these agents to investigate how targeted immune-cell engagement produces tumor killing and how that activity can be improved. Research questions commonly include selecting suitable tumor-associated antigens, characterizing T-cell activation, examining treatment resistance, and evaluating strategies intended to increase efficacy or safety. This makes the approach useful for connecting molecular design with cancer immunotherapy outcomes.
Their research relevance extends across blood cancers and solid tumors because the strategy is organized around engaging a selected tumor-associated antigen with T-cell activity. Investigators can compare how antigen choice, immune activation, and resistance affect performance in different cancer settings. These comparisons support efforts to adapt the approach while addressing the distinct challenges of efficacy and safety.
A study can examine whether the engineered interaction activates T cells, promotes release of cytotoxic molecules, and results in destruction of the engaged target cell. Researchers can also assess how antigen selection and treatment resistance influence those outcomes. Together, these observations help guide investigations into therapeutic efficacy, safety, and methods for improving immune-mediated tumor control.